ASSOCIATIONS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL WITH BIOMOLECULES IN METABOLIC DISORDERS IN YOUNG PEOPLE AGED 25–44 YEARS

Highlights

The study is devoted to the analysis of metabolic hormones and their relationship with the main risk factors for cardiovascular diseases, in particular, elevated levels of low-density lipoprotein cholesterol. The study included people under the age of 45 with active hormones.

Abstract

Aim. To assess the relationship between the levels of LDL and metabolic hormones reflecting metabolic disorders in young people.

Methods. The study included 305 people. The group 1 included 146 people with an LDL level of <2.1 mmol/L, the group 2 included 159 people with an LDL level of ≥4.2 mmol/L. Serum total cholesterol (TC), triglycerides, HDL and glucose concentrations were determined by enzymatic method using Thermo Fisher Scientific kits (Finland) on a 30i KonelabPrime clinical chemistry analyzer. The calculation of concentrations of LDL was carried out according to the Friedwald formula. The levels of amylin, C-peptide, ghrelin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 (GLP-1), glucagon, interleukin 6, insulin, leptin, monocyte chemoattractant protein-1, pancreatic polypeptide, peptide YY, tumor necrosis factor alpha were determined by multiplex analysis using the Human Metabolic Hormone V3 (MILLIPLEX) panel on a Luminex MAGPIX flow fluorimeter.

Results. In the group of patients with LDL ≥4.2 mmol/L, fasting glucose disorders were much more prevalent, the average BMI (p = 0,0001) was higher, and arterial hypertension was twice as frequent (24.8% vs. 11.6%, p = 0.003) compared with the group 1. The levels of triglycerides, TC, and glucose were higher, whereas HDL level was lower in the group 2(p = 0,0001). In patients with LDL ≥4.2 mmol/L, the values of HOMA-IR and the occurrence of IR (83.8%) according to the HOMA-IR were higher compared with the group with LDL <2.1 mmol/L (p = 0,0001). Statistically significant differences in the levels of the studied indicators between the groups 1 and 2 were obtained for C-peptide, GLP-1, insulin and leptin. The relative chance of having LDL≥4.2 mmol/L is associated with an increase in the level of C-peptide (OR = 2.042, 95% CI 1.209–3.449, p = 0.008) and a decrease in the level of GLP-1 (OR = 0.997, 95% CI 0.996–0.999, p = 0.001).

Conclusion. An increase in LDL levels in young people is associated with disorders of lipid and carbohydrate metabolism. These data are confirmed by changes in the serum metabolic markers that characterize metabolic disorders in the human body.

1. Joint committee for guideline revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018; 15: 1-29.

2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J, Cooney MT: 2016 ESC/EAS guidelines for the management of dyslipidaemias. Rev Esp Cardiol (Engl Ed). 2017; 70: 115.

3. Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015; 239: 483–495.

4. Ference B.A., Graham I., Tokgozoglu L., Catapano A.L. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J. Am. Coll. Cardiol. 2018; 72: 1141–1156. doi: 10.1016/j.jacc.2018.06.046.

5. Serdyukov DYu, Zhirkov II, Gordienko AV, Fedorova AS. Prognostic value of carbohydrate and lipid metabolism disorders at a young age. Profilakticheskaya Meditsina. 2021;24(1):60‑66. (in Russian).

6. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diab Investig. 2013; 4 (2): 108–130. doi:10.1111/jdi.12065.

7. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diab Care. 2011; 34 (S2): S251S257. doi:10.2337/dc11-s227.

8. Wang XL, Ye F, Li J, et al. Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus. Saudi Med J. 2016; 37 (1): 48-54. doi:10.15537/smj.2016.1.12035.

9. Holst J.J. The physiology of glucagon-like peptide 1. Physol. Rev. 2007; 87 (4): 1409–1439.

10. Al-Amodi HS, Abdelbasit NA, Fatani SH, Babakr AT, Mukhtar MM. The effect of obesity and components of metabolic syndrome on leptin levels in Saudi women. Diabetes Metab Syndr. 2018; 12 (3): 357-364. doi: 10.1016/j.dsx.2017.12.030.

11. Paduszyńska A, Sakowicz A, Banach M, Maciejewski M, Dąbrowa M, Bielecka-Dąbrowa A. Cardioprotective properties of leptin in patients with excessive body mass. Ir J Med Sci. 2020; 189 (4): 1259-1265. doi:10.1007/s11845-020-02211-9.

12. Vasilenko M.A., Kirienkova E.V., Skuratovskaja D.A., Zatolokin P.A., Mironjuk N.I., Litvinova L.S. Rol' produktsii adipsina i leptina v formirovanii insulinorezistentnosti u bol'nyh abdominal'nym ozhireniem. Doklady Akademii nauk. 2017; 475 (3): 336-341. doi:10.7868/S0869565217210228. (in Russian).

13. Smirnova EN, Shulkina SG. Dynamics of leptin, soluble leptin receptors, free leptin index and resistin in reducing body weight in patients with arterial hypertension associated with obesity. Arterial’naya Gipertenziya = Arterial Hypertension. 2016; 22 (4): 382–388. doi: 10.18705/1607-419X-2016-22-4-382-388 (in Russian).

14. Fedotova A.V., Chernysheva E.N., Panova T.N., Ahtjamova K.V. The relationship of serum leptin and plasma apelin levels in men with metabolic syndrome. Almanac of Clinical Medicine. 2016; 44(4):457-461. doi:10.18786/2072-0505-2016-44-4-457-461(in Russian).